Compare IPCA Labs with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PIRAMAL ENTERPRISES - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PIRAMAL ENTERPRISES IPCA LABS/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 22.8 19.0 120.4% View Chart
P/BV x 4.4 1.2 367.5% View Chart
Dividend Yield % 0.1 1.5 7.2%  

Financials

 IPCA LABS   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    IPCA LABS
Mar-18
PIRAMAL ENTERPRISES
Mar-19
IPCA LABS/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs6953,303 21.1%   
Low Rs4001,797 22.3%   
Sales per share (Unadj.) Rs260.2716.5 36.3%  
Earnings per share (Unadj.) Rs19.079.7 23.8%  
Cash flow per share (Unadj.) Rs33.1107.9 30.6%  
Dividends per share (Unadj.) Rs1.0028.00 3.6%  
Dividend yield (eoy) %0.21.1 16.6%  
Book value per share (Unadj.) Rs213.01,477.5 14.4%  
Shares outstanding (eoy) m126.20184.45 68.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.13.6 59.2%   
Avg P/E ratio x28.932.0 90.2%  
P/CF ratio (eoy) x16.623.6 70.1%  
Price / Book Value ratio x2.61.7 149.0%  
Dividend payout %5.335.1 15.0%   
Avg Mkt Cap Rs m69,120470,292 14.7%   
No. of employees `00013.37.8 169.5%   
Total wages/salary Rs m7,35922,504 32.7%   
Avg. sales/employee Rs Th2,477.416,899.4 14.7%   
Avg. wages/employee Rs Th555.22,877.7 19.3%   
Avg. net profit/employee Rs Th180.61,879.9 9.6%   
INCOME DATA
Net Sales Rs m32,836132,153 24.8%  
Other income Rs m4183,128 13.4%   
Total revenues Rs m33,254135,281 24.6%   
Gross profit Rs m4,50566,290 6.8%  
Depreciation Rs m1,7775,202 34.2%   
Interest Rs m24044,097 0.5%   
Profit before tax Rs m2,90520,119 14.4%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5118,611 5.9%   
Profit after tax Rs m2,39414,701 16.3%  
Gross profit margin %13.750.2 27.4%  
Effective tax rate %17.642.8 41.1%   
Net profit margin %7.311.1 65.5%  
BALANCE SHEET DATA
Current assets Rs m19,455122,742 15.9%   
Current liabilities Rs m10,076310,810 3.2%   
Net working cap to sales %28.6-142.3 -20.1%  
Current ratio x1.90.4 488.9%  
Inventory Days Days9823 424.4%  
Debtors Days Days6739 172.4%  
Net fixed assets Rs m20,260116,904 17.3%   
Share capital Rs m252369 68.4%   
"Free" reserves Rs m26,633272,161 9.8%   
Net worth Rs m26,886272,530 9.9%   
Long term debt Rs m2,340270,196 0.9%   
Total assets Rs m41,173856,261 4.8%  
Interest coverage x13.11.5 899.3%   
Debt to equity ratio x0.11.0 8.8%  
Sales to assets ratio x0.80.2 516.7%   
Return on assets %6.46.9 93.2%  
Return on equity %8.95.4 165.1%  
Return on capital %10.812.4 86.7%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64215,200 102.9%   
Fx outflow Rs m4,8844,889 99.9%   
Net fx Rs m10,75910,312 104.3%   
CASH FLOW
From Operations Rs m3,411-115,975 -2.9%  
From Investments Rs m-1,354-8,265 16.4%  
From Financial Activity Rs m-1,304107,525 -1.2%  
Net Cashflow Rs m753-16,650 -4.5%  

Share Holding

Indian Promoters % 45.9 52.9 86.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 4.0 285.0%  
FIIs % 25.3 26.6 95.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 16.5 105.5%  
Shareholders   36,892 93,274 39.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SHASUN PHARMA  DR. REDDYS LAB  TORRENT PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 13, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - SHASUN PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS